Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice

被引:31
作者
Kunzendorf, U [1 ]
Pohl, T [1 ]
BulfonePaus, S [1 ]
Krause, H [1 ]
Notter, M [1 ]
Onu, A [1 ]
Walz, G [1 ]
Diamantstein, T [1 ]
机构
[1] HARVARD UNIV,SCH MED,BETH ISRAEL HOSP,DIV RENAL,BOSTON,MA 02138
关键词
fusion proteins; immunoligands; immunosuppression; cell-mediated immune response;
D O I
10.1172/JCI118534
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Interleukin-2 (IL-2) plays a pivotal role in the cellular and humoral immune responses directed against foreign antigens, We characterized the in vitro and in vivo properties of a chimeric protein consisting of mouse IL-2 fused to the mouse IgG2b Fe domains. This fusion protein binds to IL-2 and Fc receptors and supports IL-2-dependent cell proliferation but does not mediate lysis of IL-2 receptor-positive cells in the presence of murine complement in vitro. However, in vivo the IL2-IgG2b fusion protein suppresses both cellular and humoral immune responses after immunization with sheep erythrocytes, Surprisingly, delayed hypersensitivity is inhibited despite a dramatic increase of splenic CD3+ and NK1.1+ lymphocytes, indicating that altered homing of IL2-IgG2b-activated lymphocytes rather than cytolysis prevents these cells from accumulating in areas of inflammation, Although in vitro the IL2-IgG2b fusion protein does not alter proliferation of B cells in response to mitogenic stimulation, IgM production in response to sheep erythrocytes is profoundly inhibited in mice treated with the IL2-IgG2b fusion protein, Since no side effects are observed, the IL2-IgG2b fusion protein may expand the therapeutic repertoire of reagents used for the treatment of allograft rejection and autoimmune diseases.
引用
收藏
页码:1204 / 1210
页数:7
相关论文
共 30 条
[1]  
ABROSION DD, 1995, SCIENCE, V268, P293
[2]   MOLECULAR-CLONING OF 2 CD7 (T-CELL LEUKEMIA ANTIGEN) CDNAS BY A COS CELL EXPRESSION SYSTEM [J].
ARUFFO, A ;
SEED, B .
EMBO JOURNAL, 1987, 6 (11) :3313-3316
[3]   CTLA4IG PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED-IMMUNITY [J].
BALIGA, P ;
CHAVIN, KD ;
QIN, LH ;
WOODWARD, J ;
LIN, JX ;
LINSLEY, PS ;
BROMBERG, JS .
TRANSPLANTATION, 1994, 58 (10) :1082-1090
[4]   RAT INTERLEUKIN-2 IMMUNOGLOBULIN-M FUSION PROTEINS ARE CYTOTOXIC IN-VITRO FOR CELLS EXPRESSING THE IL-2 RECEPTOR AND CAN ABOLISH CELL-MEDIATIED IMMUNITY IN-VIVO [J].
BOGERS, WMJM ;
LANG, F ;
PARKER, KE ;
LEMAUFF, B ;
ANEGON, I ;
JACQUES, Y ;
SOULILLOU, JP .
TRANSPLANTATION, 1994, 58 (08) :932-939
[5]   BIOLOGICAL PROPERTIES OF A CD4 IMMUNOADHESIN [J].
BYRN, RA ;
MORDENTI, J ;
LUCAS, C ;
SMITH, D ;
MARSTERS, SA ;
JOHNSON, JS ;
COSSUM, P ;
CHAMOW, SM ;
WURM, FM ;
GREGORY, T ;
GROOPMAN, JE ;
CAPON, DJ .
NATURE, 1990, 344 (6267) :667-670
[6]  
CHE SL, 1994, NAT IMMUN, V13, P258
[7]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[8]   CLUSTER-FUNCTION RELATIONSHIP OF RAT-ANTIMOUSE P55 IL-2 RECEPTOR MONOCLONAL-ANTIBODIES - INVITRO STUDIES OF THE CTL-L2 MOUSE-CELL LINE AND INVIVO STUDIES IN A DELAYED-TYPE HYPERSENSITIVITY MODEL IN MICE [J].
DANTAL, J ;
JACQUES, Y ;
SOULILLOU, JP .
TRANSPLANTATION, 1991, 52 (01) :110-115
[9]   ONE-MONTH PROPHYLACTIC USE OF OKT3 IN CADAVER KIDNEY-TRANSPLANT RECIPIENTS [J].
DEBURE, A ;
CHKOFF, N ;
CHATENOUD, L ;
LACOMBE, M ;
CAMPOS, H ;
NOEL, LH ;
GOLDSTEIN, G ;
BACH, JF ;
KREIS, H .
TRANSPLANTATION, 1988, 45 (03) :546-553
[10]   THE INTERLEUKIN-2 RECEPTOR, ITS PHYSIOLOGY AND A NEW APPROACH TO A SELECTIVE IMMUNOSUPPRESSIVE THERAPY BY ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODIES [J].
DIAMANTSTEIN, T ;
OSAWA, H .
IMMUNOLOGICAL REVIEWS, 1986, 92 :5-27